DLI after haploidentical BMT with post-transplant CY

A. Ghiso, A. M. Raiola, F. Gualandi, A. Dominietto, R. Varaldo, M. T. Van Lint, S. Bregante, C. Di Grazia, T. Lamparelli, F. Galaverna, A. Stasia, S. Luchetti, S. Geroldi, R. Grasso, N. Colombo, A. Bacigalupo

Research output: Contribution to journalArticlepeer-review


Forty-two patients relapsing after an unmanipulated haploidentical BM transplant and post-transplant CY (PT-CY), were given 108 DLI, with median interval from transplant of 266 days (range, 67-1372). DLI were given at escalating doses, expressed as CD3+ cells/kg, without GVHD prophylaxis, and ranged from 1 × 103 to 1 × 107 cells/kg (median 5 × 105 cells/kg). The average number of DLI per patient was 2.6 (range, 1-6). The diagnosis was leukemias (n=32) grafted with a myeloablative regimen and Hodgkin's disease (n=10), grafted with a nonmyeloablative regimen. Leukemic patients with molecular relapse (n=20), received DLI alone (n=17) or in association with azacytidine (n=3); leukemic patients with hematologic relapse (n=12) received chemotherapy followed by DLI (n=11) or DLI alone (n=1); Hodgkin patients received DLI following 1-3 courses of chemotherapy. In these three groups the incidence of acute GVHD II-III was 15%, 17% and 10%; response rate was 45%, 33% and 70%; 2-year actuarial survival was 43%, 19% and 80% respectively. This study confirms that escalating doses of DLI can be given in the haploidentical setting with PT-CY, with a relatively low risk of acute GVHD. Response rates and survival are dependent on the underlying disease.

Original languageEnglish
Pages (from-to)56-61
Number of pages6
JournalBone Marrow Transplantation
Issue number1
Publication statusPublished - Jan 10 2015

ASJC Scopus subject areas

  • Hematology
  • Transplantation
  • Medicine(all)


Dive into the research topics of 'DLI after haploidentical BMT with post-transplant CY'. Together they form a unique fingerprint.

Cite this